Mixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinoma |
| |
| Institution: | 1. Centre Eugène Marquis, INSERM UMR-S 991, Avenue de la Bataille Flandres-Dunkerque, CS 44229, F-35042 Rennes, France;2. ENSCR, CNRS UMR 6226, 11, Allée de Beaulieu, CS 50837, F-35708 Rennes, France;3. Université Européenne de Bretagne, F-35000 Rennes, France;1. The Key Laboratory of Beam Technology and Materials Modification of the Ministry of Education, Beijing Normal University, Beijing 100875, China;2. College of Nuclear Science and Technology, Beijing Normal University, Beijing 100875, China;3. Beijing Radiation Center, Beijing 100875, China;4. Center for Disease Control and Prevention of Beijing, Beijing 100013, China;1. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia;2. The University of Melbourne, Parkville, VIC, Australia;3. Ludwig Institute for Cancer Research, Melbourne Branch, VIC, Australia;4. Ecole National Supérior de Chimie de Rennes, Rennes, France;1. Nuclear Science and Technology Research Institute (NSTRI), Iran;2. Department of Physics, K. N. Toosi University of Technology, Iran |
| |
| Abstract: | Yttrium-90 is a radioelement which has found wide use in targeted radionuclide therapy because of its attractive physical and chemical properties. Radioembolisation of hepatocellular carcinoma with radiolabelled Lipiodol is a method of choice. We have synthesised a series of alkyldithiocarbamate yttrium complexes, easily extracted into Lipiodol due to their high lipophilicity. Among the prepared series, a new radioconjugate, which is stable over an extended period of time, has been prepared, and could represent a potential treatment procedure for hepatocellular carcinoma. |
| |
| Keywords: | Dithiocarbamate 1 10-phenanthroline Hepatocellular carcinoma Lipiodol Radionuclide therapy Yttrium-90 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
